Cancer Ongoing 2021 North Shore NSW


This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared with platinum-based in the adjuvant setting.

Trial overview

Lung cancer
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer.
Eligibility criteria

Non-Small Cell Lung Cancer with an ALK mutation requiring treatment after curative surgery.

Study details

There is a screening period to assess eligibility. Patients are randomised to the current standard of care (chemotherapy) or alectinib, a targeted treatment. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.

Further information

For more information regarding this clinical trial click here.


North Shore NSW